TEM
Tempus AI, Inc. Class A Common StockTEM
TEM
About: Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Employees: 2,300
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
59% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 27
53% more call options, than puts
Call options by funds: $78.1M | Put options by funds: $51.2M
42% more capital invested
Capital invested by funds: $1.49B [Q2] → $2.12B (+$629M) [Q3]
28% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 18
20% more funds holding
Funds holding: 80 [Q2] → 96 (+16) [Q3]
20% more funds holding in top 10
Funds holding in top 10: 5 [Q2] → 6 (+1) [Q3]
1.46% less ownership
Funds ownership: 26.66% [Q2] → 25.2% (-1.46%) [Q3]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$54
52%
upside
Avg. target
$63
78%
upside
High target
$74
108%
upside
6 analyst ratings
3 positive
50%
3 neutral
50%
0 negative
0%
B of A Securities Michael Ryskin 75% 1-year accuracy 3 / 4 met price target | 52%upside $54 | Neutral Maintained | 13 Dec 2024 |
Wolfe Research Doug Schenkel 40% 1-year accuracy 2 / 5 met price target | 69%upside $60 | Outperform Initiated | 13 Dec 2024 |
Guggenheim Subbu Nambi 50% 1-year accuracy 4 / 8 met price target | 108%upside $74 | Buy Initiated | 9 Dec 2024 |
Piper Sandler David Westenberg 69% 1-year accuracy 27 / 39 met price target | 97%upside $70 | Neutral Reiterated | 12 Nov 2024 |
Stifel Daniel Arias 22% 1-year accuracy 4 / 18 met price target | 83%upside $65 | Hold Downgraded | 11 Nov 2024 |
Financial journalist opinion
Based on 9 articles about TEM published over the past 30 days
Negative
MarketBeat
1 day ago
Tempus AI: A Potential Double-Bagger After Recent Pullback
In mid-August, around two months after Tempus AI's NASDAQ: TEM initial public offering (IPO), the stock was up a marvelous 93%. However, shares have experienced wild volatility and are now 8% below their opening price of $37 as of the Dec. 18 close.
Neutral
Business Wire
3 days ago
Tempus Now an In-Network Provider for Blue Cross Blue Shield Illinois, Blue Shield California, and Avalon Healthcare Solutions
CHICAGO--(BUSINESS WIRE)--Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the company has signed agreements for in-network provider status with Blue Cross Blue Shield (BCBS) of Illinois, Blue Shield of California, and Avalon Healthcare Solutions, a laboratory benefit manager. As part of the agreement with Avalon, Tempus is a participating provider with BCBS North Carolina, BCBS South Carolina, BCBS Vermont, Capital Blu.
Positive
Seeking Alpha
3 days ago
Tempus AI: Recent Weakness Presents Gift Ahead Of The Holidays
Tempus AI has strong long-term potential in healthcare technology, despite recent stock volatility due to lock-up period expiration and insider selling. The company's innovative "Intelligent Diagnostics" leverages generative AI and a vast proprietary dataset to drive personalized treatment options, positioning it as a leader in precision medicine. Financially, Tempus shows robust revenue growth but remains unprofitable; recent acquisitions and ongoing investments aim to strengthen its market position and path to profitability.
Neutral
Business Wire
4 days ago
New CMS Decision Provides Medicare Coverage for the Clinical Use of the Tempus ECG-AF Device
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the impact of a new decision by the Centers for Medicare and Medicaid Services (CMS) that will allow reimbursement for assessments of cardiac dysfunction using the Tempus ECG-AF algorithm. ECG-AF is one of just a few FDA-authorized medical technologies in the country to be impacted by the new CMS decision, and this milestone all.
Neutral
Business Wire
5 days ago
Personalis and Tempus Expand Collaboration to Biopharma
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) announced today that the companies have expanded their commercial relationship. The companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Tempus is serving as the exclusive commercial diagnostic partner for Personalis' ultra-sensitive tumor-informed MRD pr.
Positive
Seeking Alpha
1 week ago
Tempus AI: Why I'm Buying This AI Stock
Tempus AI's strategic acquisitions and partnerships, including Ambry Genetics and a JV with SoftBank, bolster its growth and competitive edge in AI health tech. The revenue growth and gross margins for Tempus AI's Data & Services division position Tempus AI for significant future profitability and cash flow. AI-driven automation and advanced machine learning algorithms enhance operational efficiency, reducing costs and accelerating data analysis for better client insights.
Positive
Zacks Investment Research
3 weeks ago
Will Ambry Genetics Acquisition Drive Tempus AI's Prospects?
TEM acquires Ambry Genetics, expanding its testing portfolio and redefining precision medicine.
Neutral
Business Wire
3 weeks ago
Tempus to Participate in the Piper Sandler 36th Annual Healthcare Conference
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, held in New York, New York. Tempus Founder and CEO, Eric Lefkofsky, will participate in a fireside discussion at the conference on Tuesday, December 3, 2024, at 3:00 p.m. ET. About Tempus Tempus is a technology company advancing precision medic.
Positive
Schwab Network
4 weeks ago
The Big 3: CRWD, CVNA, TEM
@ProsperTradingAcademy's Charles Moon is bullish on all of today's Big 3. He points to Crowdstrike's (CRWD) recovery and Carvana (CVNA) coiling to the upside as positive markers but warns of volatility when it comes to Tempus AI (TEM).
Positive
Seeking Alpha
1 month ago
Tempus AI: Pioneering The Future Of Precision Medicine Through AI-Driven Innovation
Tempus AI, Inc. founded in 2015, leverages AI for precision medicine, showing strong growth since its June 2024 listing, presenting a buying opportunity. The company boasts a vast clinical and molecular data library, advanced AI algorithms, and strategic partnerships with pharmaceutical giants like Merck and BioNTech. Despite profitability concerns and high cash burn, Tempus AI's revenue growth, strategic acquisitions, and unique data assets create a compelling long-term investment.
Charts implemented using Lightweight Charts™